Hypertrophy, characterized by an increase in the size of heart muscles, is a prevalent response to pressure overload, commonly stemming from conditions such as hypertension or aortic stenosis. Chronic hypertrophy ultimately leads to heart failure, a condition that poses one of the most substantial public health burdens worldwide. Understanding the pathways that govern these processes is crucial for developing effective therapeutic strategies.

The study effectively highlights the differential role of PRMT5 by employing genetically modified mouse models. Researchers discovered that cardiac-specific overexpression of PRMT5 led to pronounced cardiac dilation and worsening heart function. This finding is particularly alarming as it suggests that higher levels of PRMT5 are decidedly detrimental in the context of cardiac stress. The implications of these observations could reshape how clinicians approach the management of hypertrophy and the potential for cardiac failure in affected patients.

Moreover, the study meticulously outlines the molecular mechanisms through which PRMT5 exerts its effects. It was observed that PRMT5 interacts with various proteins critical for maintaining cardiac function. This interaction results in a cascade of biochemical events that culminate in adverse cardiac remodeling. The ability to pinpoint specific interactions underscores the potential for targeted interventions aimed at mitigating PRMT5 activity as a therapeutic strategy.

Beyond the biochemical pathways, the researchers also scrutinized the influence of PRMT5 on gene expression within cardiomyocytes, the heart’s muscle cells. The overexpression of PRMT5 was linked to the upregulation of genes associated with hypertrophic signaling and fibrosis, which invariably lead to impaired cardiac function. The identification of this gene regulatory network lays the groundwork for investigating novel therapeutic targets that could reverse the deleterious effects of pressure overload.

As heart failure, particularly due to pressure overload-induced hypertrophy, presents a multifactorial problem, the study emphasizes the need for a comprehensive understanding of underlying molecular targets. PRMT5, once regarded as an enzyme with a largely peripheral role in cardiology, is now emerging as a significant contributor to heart disease pathology. This paradigm shift necessitates a reevaluation of existing treatment modalities, which have, until now, largely overlooked the implications of post-translational modifications in cardiomyocytes.

The research elucidates that the cardiac ramifications of PRMT5 extend beyond mere hypertrophy. The study’s findings indicate a pronounced increase in apoptosis within cardiomyocytes, emphasizing the enzyme’s role not just in hypertrophic signaling but also in cell survival pathways. This revelation is groundbreaking, as it suggests that strategies aimed at modulating PRMT5 levels could address not only hypertrophy but also prevent the loss of cardiomyocytes that often worsens heart failure prognosis.

Methodologically, the researchers employed a variety of advanced techniques, including RNA sequencing and mass spectrometry, to map the changes in cardiac tissue comprehensively. These analyses provided critical insights into the proteins and pathways that are influenced by PRMT5 overexpression. The meticulous approach underscores the robustness of their findings, paving the way for future investigations into pharmacological inhibitors that could selectively target PRMT5 activity in cardiac tissue.

In light of the findings, there is a pressing need to communicate these results effectively to the broader scientific community and public health stakeholders. This research not only advances our understanding of heart biology but also opens avenues for novel therapies that could dramatically enhance patient outcomes in hypertensive heart disease. The urgency of addressing heart failure, especially in an aging population, lends additional weight to the significance of this study.

As investigations continue, future studies are warranted to explore the potential of developing PRMT5 inhibitors as therapeutic agents. Such inhibitors could be a game changer in the clinical management of hypertrophic cardiomyopathy, thereby improving the quality of life for millions globally. The path forward involves a rigorous exploration of the safety and efficacy of these inhibitors in clinical settings.

Overall, the findings from Katanasaka and colleagues propel PRMT5 into the spotlight, challenging longstanding narratives surrounding cardiovascular disease and signaling a new era of therapeutic exploration. The intricate relationship between PRMT5 and cardiac hypertrophy and failure beckons further research, potentially leading to advancements in personalized medicine approaches for heart disease management.

In conclusion, the groundbreaking study elucidates critical pathways by which PRMT5 contributes to pressure overload-induced hypertrophy and subsequent heart failure. As researchers delve deeper into the mechanisms at play, the hope is to develop targeted therapies that could alleviate the clinical burdens associated with heart disease. The promising results from this research represent not just a leap forward in understanding fundamental cardiac biology but also a beacon of hope for innovative treatments that can ultimately improve patient care and outcomes.

Subject of Research: The role of PRMT5 in cardiac hypertrophy and heart failure.

Article Title: Correction: Cardiac-specific overexpression of PRMT5 exacerbates pressure overload-induced hypertrophy and heart failure.

Article References:

Katanasaka, Y., Sunagawa, Y., Sakurai, R. et al. Correction: Cardiac-specific overexpression of PRMT5 exacerbates pressure overload-induced hypertrophy and heart failure.
J Biomed Sci 32, 80 (2025). https://doi.org/10.1186/s12929-025-01174-2

Image Credits: AI Generated

DOI: 10.1186/s12929-025-01174-2

Keywords: PRMT5, cardiac hypertrophy, heart failure, pressure overload, cardiomyocytes, gene expression, therapeutic targets.

Dr. Mehran, serving as Director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Wiener Cardiovascular Institute of the Icahn School of Medicine at Mount Sinai, has been a pivotal figure in the global cardiology community. Her work primarily focuses on devising novel randomized clinical trials and outcome research frameworks that ensure high standards of evidence-based practice. Her scientific influence extends through her prolific authorship of over 2,000 peer-reviewed articles, influencing clinical guidelines and therapeutic strategies for acute and chronic cardiovascular conditions.

One of the technical hallmarks of Dr. Mehran’s research resides in personalized cardiovascular medicine. She has been instrumental in developing validated individual risk scores that predict the probability of procedural complications such as bleeding and acute kidney injury. These risk stratification tools represent a vital advancement for tailoring therapeutic interventions to individual patient risk profiles, thereby improving procedural safety and optimizing overall clinical outcomes.

Her research methodology uniquely integrates large-scale, multicenter randomized trials with sophisticated outcome analytics, advancing the understanding of interventional procedures such as percutaneous coronary intervention (PCI). By meticulously examining factors that influence procedural success and patient recovery, her work enables clinicians to refine pre-procedural assessments and post-procedural management, mitigating complications and enhancing long-term cardiovascular health.

Dr. Mehran’s influence transcends individual clinical trials. She has played an essential role in shaping international cardiovascular practice guidelines through her consistent participation in guideline committees. Her contributions have fostered consensus on managing complex cardiovascular diseases, particularly in tailoring interventions based on risk stratification, which has been a foundational paradigm shift toward precision cardiovascular care.

Leadership is a recurring theme in Dr. Mehran’s career. She holds prominent roles including the vice presidency on the Board of Trustees at the American College of Cardiology (ACC) for 2025-2026 and serves as Chief Scientific Officer of the Cardiovascular Research Foundation (CRF). Through these influential platforms, she champions innovative research agendas and fosters collaborative networks that accelerate scientific discovery and clinical translation globally.

In addition to her robust academic and clinical research endeavors, Dr. Mehran has pioneered programs addressing gender disparities in cardiovascular medicine. She leads the Lancet Commission on Women’s Cardiovascular Diseases, an initiative mobilizing global expertise to elucidate sex-specific differences in cardiovascular physiology, disease progression, and therapeutic responses. This work aims to bridge critical knowledge gaps and promote equitable clinical trial representation.

Further advancing women’s cardiovascular health, Dr. Mehran directs the Women’s Heart and Vascular Center at Mount Sinai Fuster Heart Hospital. This center integrates multidisciplinary approaches catering exclusively to female patients’ unique pathophysiological and psychosocial cardiovascular risk factors. This integration exemplifies the transition toward specialized clinical pathways that acknowledge and address sex-specific cardiovascular manifestations.

Among her many accolades, Dr. Mehran has garnered numerous elite awards that signify her extensive impact on cardiology and medical science. Highlights include the 2016 American College of Cardiology’s Bernadine Healy Leadership Award, the 2019 European Society of Cardiology Silver Medal, the 2024 Icahn School of Medicine’s Jacobi Medallion, and notably, the 2025 ESC Gold Medal. These awards reflect both her scientific excellence and leadership in fostering research innovations.

Mount Sinai Health System, home to Dr. Mehran’s distinguished career, ranks among the world’s preeminent centers for cardiovascular care and research. The Mount Sinai Fuster Heart Hospital is nationally acclaimed, positioning second in the United States for cardiology and heart surgery according to U.S. News & World Report, and is recognized globally by Newsweek among the top specialized hospitals. This institutional excellence synergizes with Dr. Mehran’s work, creating an environment conducive to cutting-edge cardiovascular discoveries.

The recognition by the ESC not only celebrates Dr. Mehran’s individual achievements but also elevates the visibility of interventional cardiology’s evolving landscape. Interventional cardiology has rapidly progressed with advancements in device technology, procedural techniques, and perioperative pharmacotherapy, all areas where Dr. Mehran’s research has been influential. Her work has emphasized the seamless fusion of bench research with bedside applications, ensuring that innovative therapies translate into tangible clinical benefits.

This award highlights the pivotal role of mentorship and collaborative science in cardiovascular medicine. Dr. Mehran consistently emphasizes that such honors reflect the collective efforts of diverse teams, including junior investigators, clinical collaborators, and institutional support systems. Her commitment to nurturing the next generation ensures ongoing progress in a field that demands continuous innovation to combat the global burden of cardiovascular diseases.

The cardiovascular research community worldwide acknowledges that addressing the multifaceted challenges of cardiovascular disease requires dynamic leadership and interdisciplinary collaboration. Dr. Mehran’s career exemplifies this holistic approach, integrating clinical insights, methodical research, and advocacy for inclusivity and equity in medicine. The ESC Gold Medal serves as a beacon of scientific rigor, leadership, and dedication to patient-centered innovation in cardiovascular health.

As cardiovascular diseases remain a leading cause of global morbidity and mortality, the scientific contributions of thought leaders like Dr. Mehran are fundamental to improving outcomes. Her pioneering efforts in stratifying patient risk, refining interventional procedures, and addressing sex-specific disparities represent critical strides toward personalized cardiology and equitable healthcare. The broader impact of her work is undeniable in shaping the future landscape of cardiovascular medicine.

Subject of Research: Cardiovascular medicine, Interventional cardiology, Personalized risk assessment, Women’s cardiovascular health

Article Title: Dr. Roxana Mehran Awarded the European Society of Cardiology Gold Medal for Transformative Contributions to Cardiovascular Medicine

News Publication Date: August 29, 2025

Web References:

• https://mediasvc.eurekalert.org/Api/v1/Multimedia/4f02774c-7860-4824-909b-af93660b348d/Rendition/low-res/Content/Public
• https://www.mountsinai.org/
• https://www.escardio.org/

References: Not provided in original content

Image Credits: Mount Sinai Health System

Keywords: Cardiology, Cardiovascular disorders, Interventional cardiology, Clinical trials, Personalized medicine, Women’s cardiovascular health, Cardiovascular research, ESC Gold Medal